TL;DR: For most seed funding rounds, a post-money SAFE is the default because it’s fast, market-familiar, and makes dilution easier to estimate when you’re stacking multiple checks. Use a convertible note when a real maturity clock is part of the deal (for example, a bridge with time pressure), or when the investor won’t write the check without debt-style protections. Either way, don’t let “simple paper” hide the real terms that drive outcomes: cap/discount, post-money vs pre-money, side letters, and what happens in an acquisition.
If you’re raising seed funding, you’ll almost always hear some version of: “Should I raise on a SAFE or a convertible note?” The honest answer is that either can work, but they fail in different ways. A SAFE (Simple Agreement for Future Equity) means an investor pays you now for the right to receive equity later. A convertible note is a loan that is designed to convert into equity later, usually in your next priced round, and it often has the same conversion economics as a SAFE: a price cap and/or a discount).
Decision rule: in most seed funding situations, you should start from a post-money SAFE and make someone tell you why you need something more complicated. It’s usually the cleanest option when you’re taking multiple small-to-medium checks, because you can model dilution with less guesswork and you avoid a maturity deadline showing up at the worst time. A convertible note can still be the right tool if the investor requires a maturity date, you’re doing a true bridge where time pressure is part of the bargain, or you’re in a context where debt-like terms are the only way to get the round done. You’re trading speed and simplicity for either (a) a maturity clock that can turn into leverage against you, or (b) more documentation and negotiation in a priced round.
How to use this seed funding guide
If you’re skimming, read the “Seed funding instruments, in one screen” table, then jump to the section that matches what you’re doing next. If you’re mid-raise, focus on the negotiation playbook and the side-letter sections. If you’re about to sign a term sheet for a priced seed round, read the light preferred section and the option pool callouts twice.
Start here if you’re raising your first $250k–$1.5m: Read “Seed funding instruments, in one screen,” then the SAFE sections (post-money vs pre-money, cap/discount, side letters).
Start here if you already have SAFEs/notes outstanding: Read “Cap table hygiene” and “Seed funding edge cases” before you sign anything else.
Start here if a lead wants a small priced seed round: Read “Light preferred seed rounds” and the option pool and protective provisions callouts.
What this seed funding guide covers and what it doesn’t
How SAFEs and convertible notes work in seed funding, including conversion triggers, caps, discounts, and MFN.
How to compare a SAFE, a note, an accelerator deal, and a “light” priced preferred seed round.
The few terms that actually drive founder outcomes: dilution mechanics, maturity pressure, pro rata, and side-letter creep.
A practical negotiation playbook: what to push on, what to accept, and what to model before you sign.
Seed funding instruments, in one screen
At seed, you’re usually trying to do two things at once: buy time (runway) and buy credibility (a cap table and story that supports the next round). The instrument you pick changes how much time pressure you’re under, how predictable dilution is, and how messy your next financing becomes.
Can satisfy investors who want “real paper”; maturity can motivate a priced round.
Maturity date becomes leverage against you; interest increases conversion amount; defaults create ugly negotiations.
Accelerator deal
Usually a small investment plus program terms; often equity or a SAFE plus rights.
Signaling and network can help you raise the rest of the seed round.
Terms can include information rights, MFN, or pro rata that complicate later rounds.
Light preferred seed round
A priced round selling preferred stock (often “Series Seed” or even “Series Pre-Seed“).
Clarity: you set a valuation now and clean up the cap table.
Higher legal cost and more negotiation: liquidation preference, protective provisions, option pool, etc.
A quick seed funding decision tree
If you want speed, minimal negotiation, and no maturity pressure, start with a post-money SAFE.
If an investor insists on a maturity date or you’re doing a bridge where time pressure is part of the deal, consider a convertible note.
If you have a true lead, you want to clean up multiple SAFEs/notes, or you need valuation clarity now, consider a priced seed round.
If the “value” is the program and network, not the check, an accelerator can be worth it, but treat side-letter rights like real deal terms.
What investors optimize for in seed funding
In a SAFE, most investors are optimizing for clean economics and “no regrets” protection if you raise at a much higher price later. That’s why caps, discounts, and MFN show up early, even when nobody wants to negotiate governance yet.
In a note, investors are also buying leverage. The maturity date gives them a conversation starter if the next round slips, and the qualified financing definition gives them a say in what “counts” as a real priced round. In a priced seed round, investors are explicitly buying governance and downside protections, so it’s normal to spend time on boards, vetoes, and liquidation preference.
How SAFE conversion math works
A SAFE converts by translating the investor’s purchase amount into a number of shares at a conversion price set by the next priced round, but adjusted by the SAFE’s economics. Practically, you can think of it as the investor getting the better of two deals: the deal implied by the valuation cap, or the deal implied by the discount.
One nuance: post-money SAFEs make it easier to estimate ownership sold at signing, but the final number of shares can still move based on the priced round’s terms, especially if the round valuation is at or near the cap and you also change the option pool right before closing. The point is not perfect precision early. The point is avoiding surprise dilution and making sure you understand which levers can still move later.
Mini-example: valuation cap conversion using a post-money SAFE
If you invest $500k on a $10m post-money cap, your back-of-the-napkin ownership estimate is about 5% ($500k ÷ $10m), before the next round’s new money and any option pool increase. That “ownership sold is transparent” feature is the core reason post-money SAFEs became the default form.
Mini-example: discount vs cap and which one wins
Say your SAFE has a 20% discount and a cap. If the Series A price is high, the cap usually produces a lower conversion price than the discounted Series A price, so the cap drives. If the Series A price is modest and below the cap, the discount can be the better deal. Either way, most forms are built so the investor converts at the lower price per share (which means more shares).
Seed funding with SAFEs: what’s actually being sold
A SAFE is not equity today and it’s not a loan. It’s a promise that the investor will receive shares later if a defined trigger happens, usually an equity financing where you sell preferred stock. That design is why SAFEs are fast. They intentionally avoid negotiating the “full stack” of preferred terms until a priced round.
Most founder attention goes to the next priced round, but don’t ignore the other triggers. In an acquisition (a “liquidity event”), SAFEs may convert or pay out under formulas that can surprise you if the exit is small. In a wind-down, SAFEs sit behind creditors, so “we’ll just return the money” can be unrealistic if the company has real liabilities.
Post-money SAFE vs pre-money SAFE (why it matters)
With a post-money SAFE, you can usually estimate dilution at signing because the investor’s ownership is measured after the SAFE money is counted, but before the next round’s new money. With a pre-money SAFE, each additional SAFE can dilute earlier SAFEs as well as you, so the final ownership math stays uncertain until conversion.
Example: if you raise $500k on a $10m post-money cap, you’re selling roughly 5% on that SAFE ($500k ÷ $10m), before you account for the option pool and the next round’s dilution. The mistake I see is founders negotiating the cap for weeks, then casually letting investors use a pre-money template or stacking multiple capped SAFEs without re-running the cap table model. That’s how “we sold ~10% at seed” turns into “we sold ~20% before the Series A term sheet even arrived.”
Valuation cap, discount, and MFN: the 3 SAFE terms that matter
A valuation cap is the maximum valuation used to set the SAFE’s conversion price, so a lower cap generally means more shares for the investor at the next priced round. A discount is an alternative conversion mechanism, typically a percentage off the next round’s price per share. If a SAFE has both, the investor usually converts at whichever is better for them.
An MFN (most favored nation) clause lets an early investor opt into later, more favorable terms you offer to someone else. Investors ask for this because they know the “round” can stretch for months, and they don’t want to be punished for moving first. From your side, MFN becomes dangerous when it’s vague, when it applies to side-letter rights (not just economics), or when you’re issuing multiple instruments and nobody can tell what “more favorable” means.
Side letters: where a “simple” SAFE round stops being simple
In practice, I keep seeing founders treat side letters like a minor add-on. They’re not. Side letters are where investors request pro rata rights, information rights, or even board observer rights long before a priced round.
If you grant pro rata, try to tie it to the next equity financing only (not every future round), and define who gets it (for example, only investors above a “major investor” threshold). If you grant information rights, keep them lightweight and aligned with what you already produce. You’re trading fundraising speed for future allocation and admin burden, so the right question is: “Will this make my Series A harder to lead?”
Seed funding with convertible notes: the maturity date is the whole point
A convertible note is debt. That sounds obvious, but it’s the source of most of the leverage. Economically, though, notes often look a lot like SAFEs because they commonly include a valuation cap and/or discount in addition to interest, a maturity date, and conversion in a “qualified financing” above a dollar threshold. If the qualified financing doesn’t happen by maturity, you’re negotiating from a weaker position than you were on the day you took the money.
Interest: usually not the economic driver, but it adds up
Founders often fixate on whether the interest rate is 4% or 8%. Most of the time, the valuation cap and discount matter more, and the interest is secondary. But it becomes material if you’re extending notes repeatedly or you’re close to maturity, because accrued interest increases the conversion amount and can change pro rata math in the next round.
Maturity: the negotiation you don’t want to have
Theory: maturity is just a date and everyone extends.
Reality: maturity is when a reasonable investor asks, “Why hasn’t the priced round happened?” and starts pricing in risk. In a good scenario, you extend maturity for more time. In a bad scenario, investors ask for better economics, extra rights, or immediate conversion into a shadow preferred round.
From the investor’s perspective, maturity is downside protection and a forcing function. They’re optimizing for not being stuck indefinitely in a non-equity instrument with no liquidity path. If you’re doing a note, try to avoid a maturity date that’s shorter than your realistic fundraising and product timeline, and be careful with a qualified financing threshold that’s higher than what you could plausibly close in a tough market.
Accelerators and seed funding: don’t ignore the “small print”
Accelerators can be a great seed funding catalyst because they bundle a small check with a distribution channel: intros, a demo day, and credibility. But because the check is “small,” founders sometimes stop reading when they see the headline. Don’t. The program terms can include equity, a SAFE, or other rights that show up later when you’re trying to run a clean priced round.
Common accelerator asks: MFN, pro rata, and “major investor” treatment
The recurring pattern is “just give us MFN” or “just give us pro rata,” framed as standard. Sometimes it is standard. But it can also create a pre-allocation problem in your next round, especially if several early investors all have pro rata rights and the Series A lead wants to control allocation. If you have leverage, limit these rights to the next round only and make sure they don’t automatically expand into full investors’ rights agreements later.
“Light preferred” seed rounds: when a priced round is worth it
A light preferred seed round is just a priced equity round with fewer sharp edges than a full Series A. You sell preferred stock at a negotiated valuation, and you adopt a set of preferred rights and governance terms that will look familiar to venture capital investors.
The seed terms that matter (and why they show up)
Liquidation preference determines who gets paid first in an exit. In most founder-friendly seed rounds, you’re pushing for 1x non-participating, because it protects investor downside without double-dipping on upside. Protective provisions are investor veto rights over major actions. The negotiation is usually about scope, not whether they exist.
Option pool sizing is where “valuation” quietly moves. If the investor requires a larger unallocated option pool to be created pre-money, you take that dilution immediately. Board composition and observer rights shape control. Pro rata rights can be reasonable for a lead who is truly committing, but they can also crowd out new money if you hand them out too broadly.
Seed funding red flags and what to do instead
Most seed terms are not “good” or “bad” in the abstract. The red flags are the ones that (1) create hidden dilution, (2) hand out long-term rights with no lead investor, or (3) add leverage against you without buying you real time or certainty. A red flag is not automatically a deal-breaker, but it can become a real headwind if you accumulate several of them early, because later investors often ask you to unwind or harmonize the mess.
Red flags in a SAFE round
Different caps for different investors, with no “round close” plan: you can accidentally sell far more of the company than you intended. Fix: set one cap/discount for the round, pick a target amount, and treat any change as a new close with a clean cutoff date.
MFN that applies to side-letter rights (not just economics): a single later side letter can retroactively upgrade everyone. Fix: narrow MFN to cap/discount terms only, or define exactly which rights are covered.
Pro rata granted to lots of small checks: it can crowd out your next lead and create allocation fights. Fix: reserve pro rata for major investors and limit it to the next equity financing.
“We’ll clean it up later” paperwork: missing approvals and scattered PDFs become expensive diligence work. Fix: run a simple closing checklist and keep one tracked schedule of SAFEs and side letters.
Red flags in a convertible note round
Short maturity relative to your runway and fundraising reality: it can turn into investor leverage right when you have the fewest options. Fix: align maturity with a realistic timeline, and be explicit about extension mechanics up front.
Qualified financing threshold that’s higher than what you can plausibly close: you can end up with “stuck” debt that doesn’t convert. Fix: set a threshold that matches the kind of round you can actually lead at your stage.
Multiple note forms with inconsistent definitions: conversion becomes spreadsheet archaeology and invites disputes. Fix: standardize one form and one definitions section across investors.
Hidden economics (cap/discount) plus extra rights: if you’re giving both debt leverage and heavy side-letter rights, you’re paying twice. Fix: pick one “hard thing” per instrument: either the maturity clock, or the extra rights, and keep the rest plain.
Red flags in accelerators and light preferred rounds
Accelerator rights that pre-allocate your next round: broad pro rata for small checks or MFN that upgrades rights, not just price. Fix: treat accelerator side letters like real financing terms and keep them “next round only.”
Light preferred round with a big pre-money option pool requirement: your effective valuation drops even if the headline valuation looks great. Fix: model the option pool impact alongside valuation and negotiate the pool size like it’s economics (because it is).
Protective provisions that feel like Series A control at seed: founders can end up with unexpected vetoes on day-to-day actions. Fix: narrow the veto list to true major actions and keep operational decisions with the board/common where market allows.
If you see 2+ of these at once at your seed funding round
When two or more red flags show up in the same seed round, the right move is usually not “negotiate harder” in the abstract. It’s to simplify the deal structure, standardize the paper, and reset expectations before you accumulate rights that a future lead investor will want to unwind.
Pick a single instrument and one set of economics for the rest of the round, and set a clear close date.
Standardize side letters (or stop issuing them) and create one tracked schedule of who has which rights.
If you already have multiple instruments outstanding, consider whether a priced seed round is the clean reset that saves time later.
Cap table hygiene: how seed documents become a diligence problem
By the time you’re raising a priced round, investors are not just underwriting your business. They’re underwriting whether your prior seed funding paperwork can survive diligence. The failure mode is rarely the SAFE itself. It’s the pile of inconsistent side letters, untracked MFN promises, and missing approvals that turns a clean cap table into a cleanup project.
Stacking SAFEs (especially at different caps): what goes wrong
Post-money SAFEs make each investor’s percentage easier to calculate, but that transparency cuts both ways. If you sell 8% on one cap and then sell another 8% on a different cap, nobody else is getting diluted. You are. So a “rolling” SAFE round can quietly become an outcome where founders absorb essentially all dilution from later SAFE checks.
The fix is mostly process: pick one set of SAFE economics, set a target amount, and treat anything outside that box as a decision, not an accident. If you need to change price, consider doing it with a clear “round close” and a new round, or consider whether a priced seed round is the cleaner reset once you have enough investor interest.
Side letters: the administrative nightmare and how to keep them bounded
I keep seeing the same pattern: founders keep the SAFE form standard, then hand out side letters like party favors. That’s backwards. Side letters are often where the real long-term rights live, especially pro rata and MFN, so you should standardize them and track them like you would any other cap table item.
Founder-friendly bounding moves: limit pro rata to the next equity financing, reserve it for “major investors,” and use one standard form of side letter rather than bespoke edits. Also, be explicit whether MFN covers only economics (cap/discount) or also side-letter rights. If you’re not explicit, you’re inviting a future disagreement about what “more favorable” means.
Seed funding edge cases: down rounds, small exits, and “we never raised again”
Small acquisition before a priced round
A surprising number of companies sell before a Series A. In that scenario, your SAFEs may have a payout mechanic that is not simply “everyone gets their money back.” Read the liquidity event language so you understand whether investors get a cash-out amount, a conversion amount, or a choice, and where they sit in the payout stack.
Down round or flat round
If your next priced round is at or below the cap, the cap may not drive the economics at all, and the discount can become the meaningful lever. This is also where founders sometimes discover that “post-money ownership sold” estimates were just that: estimates, because the priced round’s price, option pool changes, and the SAFE’s exact conversion language interact in ways that are easy to misread.
If you never raise a priced round
If there’s no equity financing, a SAFE can sit outstanding for a long time, and a note can mature and force a negotiation. Either way, the instrument becomes part of your company’s long-term capital structure, not a temporary bridge. That’s why you should optimize for documents you can live with, not just documents you can close quickly.
Seed funding closing checklist
Even when the paper is “simple,” you still need real corporate approvals and a clean closing set. The goal is not paperwork for its own sake. The goal is that, at the next round, you can hand over a neat folder and not spend two weeks recreating history from email threads.
SAFE round checklist
One standard SAFE form per investor, with the same economic terms unless you are deliberately running two separate “closes.”
Board approval (and stockholder approval if your charter, investor rights, or prior financing documents require it).
A tracked side-letter policy and one standard side letter template (if you are offering pro rata, MFN, or information rights).
A cap table that reflects every SAFE, including date, amount, cap/discount, and any side-letter rights.
A closing email and final PDFs saved in one place, so diligence is copy/paste later.
Convertible note round checklist
One note form per investor plus any related purchase agreement, with consistent definitions (especially “qualified financing”).
Clarity on maturity: what happens at maturity, who can extend, and whether an extension changes economics.
Clarity on economics: cap and/or discount, and whether interest converts as well as principal.
Clarity on edge cases: what happens in an acquisition before conversion, and whether repayment is ever realistic.
A cap table schedule tracking principal, interest, and any amendments, so the conversion math is not a spreadsheet archeology project.
People confuse these seed funding matters…
SAFE vs KISS: A KISS (Keep It Simple Security) is another early-stage instrument with similar goals, but it often includes different control and conversion features depending on the template.
Valuation cap vs valuation: The cap is a conversion-price mechanism, not a statement of what your company is “worth” today. It can feel like a valuation because it shows up in the math, but it only applies if your next round prices above it.
Seed funding vs Series Seed: “Seed funding” is a stage label. “Series Seed” usually refers to a priced preferred round using seed-style documents and a preferred stock designation.
A founder’s seed funding negotiation playbook
1) Set the “round box” before you negotiate individual checks
Before you take the first $25k check, decide what the round is: target amount, instrument (post-money SAFE or note), cap and/or discount, and whether you will offer MFN or pro rata. Otherwise, you’ll negotiate the “round” one investor at a time, which is like trying to build a cap table by group chat. It technically works, but you won’t like the screenshot later.
2) Model dilution using the terms you’re actually signing
Model at least three scenarios: (a) Series A at or below the cap, (b) Series A well above the cap, and (c) a smaller-than-hoped seed preferred round that converts everything. Include the option pool increase that a lead may ask for, because that dilution often lands on you, not on the new money. If you don’t have a model, you’re negotiating blind, even if you’re great at storytelling.
3) Negotiate the leverage points, not the cosmetic ones
SAFE: confirm it’s post-money, then negotiate cap/discount, and keep MFN and side-letter rights narrow.
Note: negotiate maturity, qualified financing threshold, and what happens at maturity before you argue about interest.
Any instrument: decide who gets pro rata and whether it’s limited to the next round.
Light preferred: watch the option pool and protective provisions as closely as valuation.
The practical takeaway on seed funding
If you remember one thing: in seed funding, the instrument doesn’t just price money. It prices future optionality. Pick the structure that keeps your next round leadable, then be disciplined about keeping terms consistent across investors.
What you should do this week
If you’re about to start a SAFE round: pick the post-money form, set a cap/discount policy, and write down a one-page side-letter policy (what you will and won’t give).
If you already have multiple SAFEs outstanding: model conversion and dilution before you negotiate the next one, and consider whether a seed preferred round would simplify the cap table.
If you’re considering a note: sanity-check maturity against your runway and be explicit about extension mechanics.
If a lead is pushing for a priced round: focus your energy on option pool, liquidation preference, and protective provisions, not just headline valuation.
Seed Funding FAQs
Should I raise on a SAFE or a convertible note?
If you’re choosing between them for seed funding, a post-money SAFE is usually the starting point because it closes fast and avoids maturity pressure while keeping dilution more predictable. Move to a convertible note when the investor needs a maturity date (or you’re doing a true bridge where the clock is part of the deal), and you’re comfortable with the leverage that creates if the next financing takes longer than planned.
What is a valuation cap in a SAFE?
A valuation cap sets the maximum valuation used to calculate the SAFE’s conversion price, which usually means the investor gets more shares if your next priced round is above the price cap. If your next round prices below the price cap, the price cap often doesn’t drive the math, and the SAFE converts based on the round’s actual price (or discount, if applicable).
What is a post-money SAFE and why does it matter?
A post-money SAFE measures the SAFE investor’s ownership after the SAFE money is included, which makes dilution more predictable at signing. It matters because post-money SAFEs reduce “stacking surprises,” where additional SAFEs change earlier investors’ and founders’ expected ownership percentages.
What are standard SAFE terms investors ask for?
Most investors focus on valuation cap and/or discount, and some ask for MFN protection. Separately, many meaningful “asks” show up in side letters, like pro rata rights or information rights, so you should negotiate those with the same seriousness as the headline economics.
What’s the biggest founder mistake in seed funding SAFEs?
Stacking multiple SAFEs with caps without modeling combined dilution is the most common, expensive mistake. The fix is simple: treat all SAFEs as one round, keep terms consistent, and update your cap table model before you sign the next one.
What happens if a SAFE never converts?
If there’s never a priced equity financing, the SAFE can remain outstanding until another trigger happens, like a liquidity event or dissolution, depending on the form. That’s why you should understand the acquisition payout mechanics, not just the priced-round conversion.
When should I do a priced seed round instead of SAFEs or notes?
A priced seed round can be worth it when you have a lead who wants to set terms, you want to clean up a messy stack of SAFEs/notes, or you need the signaling of “real” preferred stock for the next financing. You’ll spend more on docs and negotiate more terms, but you often buy clarity and avoid cap table drag later.
Do SAFEs give investors control rights?
Usually not. A standard SAFE is primarily economic and does not, by itself, grant voting rights, board seats, or protective provisions. But control rights can sneak in through side letters (information rights, observers) or arrive later automatically when the SAFE converts into preferred stock in a priced round.
Should I give pro rata rights in a SAFE side letter?
It can be reasonable for a true lead or a large check, because it rewards conviction and helps the investor justify doing diligence early. If you give it, keep it limited to the next equity financing and reserve it for major investors, or you risk crowding out new money in your next round.
What is a “qualified financing” in a convertible note?
It’s the defined priced round that triggers automatic conversion, usually a preferred stock financing above a minimum dollar amount. The threshold matters because it determines whether a smaller round converts the note automatically or leaves you stuck with debt that can mature.
Can I mix SAFEs and convertible notes in the same seed funding round?
You can, but it’s usually a self-inflicted complexity tax. Mixing instruments makes it harder to explain your cap table, and MFN clauses can create unexpected “cross-pollination” of terms. If you need two instruments, do it deliberately and track exactly who has what rights.
Are accelerator terms “standard,” or can I negotiate them?
Many accelerators do have standard forms, and you should expect less flexibility than a one-off angel SAFE. That said, “standard” doesn’t mean “uniform,” because programs vary on whether the investment is equity or a post-money SAFE, and whether there’s an attached pro rata side letter. If you’re comparing programs, ask for the actual documents early so you’re not learning the real tradeoffs the day before you accept.
What should I watch for in accelerator side letters?
The biggest issues are usually pro rata rights, MFN clauses, and information rights, because those terms can pre-allocate your next round or create admin burdens. If you agree to pro rata, try to keep it limited to the next equity financing and use a standard calculation formula rather than a hard ownership target. Also, be clear whether MFN covers only economics (cap/discount) or also side-letter rights.
Do accelerator deals make a Series A harder?
They can help if the accelerator improves your fundraising surface area: intros, credibility, and a tighter narrative. They can hurt if the deal adds special rights that your Series A lead now has to diligence, harmonize, or buy out. The practical rule is that you want one clean instrument and, if there are side letters, one standardized set of side-letter rights you can explain in a sentence.
What is a “light preferred” seed round?
It’s a priced seed round where investors buy preferred stock now, but the documents and negotiations are typically slimmer than a full NVCA-style Series A package. You’re paying more legal and negotiation cost up front in exchange for clarity on valuation, a cleaned-up cap table, and defined governance terms. Many founders use “Series Seed” style documents as the lightweight template for this.
In a priced seed round, what terms matter more than valuation?
Option pool size and whether it’s created pre-money can move your effective valuation more than the headline number. Liquidation preference structure and protective provisions shape your downside and control in real exits and real board moments, not just in spreadsheets. So if you’re spending negotiation time, spend it there first.
When is a priced seed round better than a post-money SAFE?
A priced seed round is often better when you have a real lead, you’re raising enough money that “defer the hard terms” stops being worth it, or you need to clean up stacked SAFEs/notes before a larger financing. It can also be the right move when you want a functioning governance setup now, rather than waiting for a Series A to define it. If you’re raising smaller checks and speed is the priority, a post-money SAFE can still be the cleanest default.
Ryan RobertsStartup Lawyer
Ryan Roberts is a startup lawyer with more than two decades of experience advising on venture financings and M&A transactions totaling more than $1 billion. He is the author of the Amazon bestselling startup law book Acceleration.
